(IN BRIEF) The largest study to date on testicular germ cell tumours (TGCTs) has revealed a potential link between testicular cancer risk and rare genetic variants affecting cellular movement and structure. Conducted by The Institute of Cancer Research, London, the … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged cancer genetics, cell movement genes, Clare Turnbull, DNA mutations, European Urology Open Science, genetic risk, heritability in cancer, Movember Foundation, personalised medicine, rare genetic variants, testicular cancer, testicular germ cell tumours, TGCT, The Institute of Cancer Research, translational genomics, UK Biobank, whole-exome sequencing, Zeid Kuzbari
(IN BRIEF) A groundbreaking AI-powered research platform, POETIC-AI, has been unveiled by scientists from The Institute of Cancer Research, promising to accelerate cancer biomarker discovery. Demonstrated at The Alan Turing Institute’s fifth AI UK conference, the platform integrates diverse clinical … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged artificial intelligence, biomarkers, cancer research, Cancer Research UK, clinical trial data, Collaborative Research, CT, digital pathology, Dr. Ferran Cardo, Dr. Maggie Cheang, hormone therapy, ICR, Integrated Discovery and Diagnostics programme, Ki67, medical imaging, MRI, natural language AI, Palantir Foundry, POETIC trial, POETIC-AI, Professor Manuel Salto-Tellez, Royal Marsden NHS Foundation Trust, The Institute of Cancer Research, Xixuan Zhu
(IN BRIEF) Scientists at The Institute of Cancer Research in London have made significant strides in understanding why some cases of neuroblastoma—a pediatric cancer of nerve tissue—result in poorer outcomes. Their research indicates that mutations in the ATRX gene, which … Read the full press release
Posted in Healthcare, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged ATRX gene, Cancer Letters, Cancer Research UK, Dr Sally George, Federica Lorenzi, high-risk, immune cell infiltration, inflammatory pathways, macrophages, MYCN gene amplification, Neuroblastoma, Neuroblastoma UK, paediatric oncology, personalised therapy, targeted treatment, The Institute of Cancer Research, TIME, tumour immune microenvironment
LONDON, 16-Nov-2017 — /EuropaWire/ — The Institute of Cancer Research, London, welcomes the approval by NICE of a new type of treatment for women with previously untreated advanced breast cancer. Palbociclib and ribociclib, two new drugs approved today for use on the NHS, … Read the full press release
Scientists have identified weak spots in cancer cells that could be targeted and attacked by new precision drugs. BRIGHTON, 2-3-2015 — /EuropaWire/ — A major computational analysis by scientists at the University of Sussex and The Institute of Cancer Research, … Read the full press release
Posted in Education, Healthcare, Science, United Kingdom
Tagged Cancer Research UK, Daphne Jackson Trust, Dr Bissan Al-Lazikani, Dr Frances Pearl, drugs that exploit the inherent weaknesses of cancer cells, Nature Reviews Cancer, Professor Laurence Pearl, Professor Paul Workman, The Institute of Cancer Research, The Institute of Cancer Research scientists, Tony Carr, University of Sussex
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?